COMPASS Pathways plc (NASDAQ:CMPS) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC grew its holdings in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 161.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 212,700 shares of the company's stock after purchasing an additional 131,300 shares during the quarter. Renaissance Technologies LLC owned about 0.31% of COMPASS Pathways worth $804,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new position in COMPASS Pathways during the fourth quarter worth $41,000. Wealthfront Advisers LLC acquired a new stake in shares of COMPASS Pathways in the 4th quarter valued at $43,000. Flagship Harbor Advisors LLC acquired a new stake in COMPASS Pathways in the fourth quarter valued at approximately $43,000. Conservest Capital Advisors Inc. increased its position in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock valued at $51,000 after acquiring an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. bought a new stake in COMPASS Pathways in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 46.19% of the company's stock.

COMPASS Pathways Price Performance

Shares of NASDAQ:CMPS traded up $0.08 during trading on Wednesday, hitting $3.72. 473,112 shares of the company's stock were exchanged, compared to its average volume of 801,302. The company has a market cap of $344.47 million, a price-to-earnings ratio of -1.69 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 52-week low of $2.49 and a 52-week high of $9.63. The business's 50-day simple moving average is $3.34 and its 200 day simple moving average is $4.07.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). As a group, equities analysts predict that COMPASS Pathways plc will post -2.33 EPS for the current year.

Wall Street Analysts Forecast Growth

CMPS has been the subject of a number of recent research reports. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a research note on Thursday, February 27th. They set a "buy" rating and a $11.00 price target for the company. Royal Bank of Canada reissued an "outperform" rating and issued a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a report on Friday, March 28th. HC Wainwright restated a "buy" rating and issued a $45.00 target price on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group cut their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, February 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $20.20.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.